Denali Therapeutics Reports Q3 2026 Earnings Driven by AVLAYAH Commercial Launch
Denali Therapeutics (DNLI) reported significant growth in its third quarter of 2026, primarily driven by the commercial launch of AVLAYAH for Hunter syndrome. Net product revenue surged to $17.8 million, up from $3.6 million in the previous full commercial quarter. The company achieved a net income of $70.1 million, a substantial turnaround from a net loss of $126.9 million in the same period last year, aided by a $194 million gain from a priority review voucher sale. Looking ahead, Denali provided optimistic Q4 2026 revenue guidance of $30 million to $32 million, representing approximately 65% growth over Q3. While management cautioned that some revenue was pulled forward due to accelerated patient transitions from clinical studies to commercial therapy, the company's expansion into 20 state Medicaid programs and increased U.S. commercial coverage (70%) signals strong market penetration.
Tickers: $DNLI
Topics: guidance net income priority review voucher product launch revenue growth